DNLI
Denali Therapeutics
$23.57
+$0.46 (+1.99%)Jul 27, 2026
Key metrics
The numbers that frame DNLI today
- Market cap
- $3.74B
- P/E (TTM)
- -7.4
- EV / FCF
- -8.5
- ROIC
- -54.4%
- Div yield
- 0%
- Debt / equity
- 0.2
- 52wk Low
- $12.58
- 52wk High
- $27.30
Growth
Revenue and earnings trend for DNLI
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about DNLI
Is Denali Therapeutics a good buy?
Hold. Denali Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks mixed. The support signal is useful, but not decisive. We think Denali Therapeutics is selling at a very high price.
What is the market capitalization of DNLI?
Denali Therapeutics's market capitalization is $3.74B.
What is the P/E ratio for DNLI stock?
Denali Therapeutics's current P/E ratio is -7.4.
What is the 52-week high for DNLI stock?
The 52-week high for Denali Therapeutics is $27.30. The current close of $23.57 is 13.7% below that high.
What is the 52-week low for DNLI stock?
The 52-week low for Denali Therapeutics is $12.58. The current close of $23.57 is 87.4% above that low.
Does DNLI stock pay dividends?
Denali Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for DNLI?
Denali Therapeutics's Debt / Equity ratio is 0.25.